NEW YORK--(BUSINESS WIRE)--The Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of investors of CorMedix, Inc. (NYSE: CRMD) resulting from allegations CorMedix may have issued materially misleading business information to the investing public.
On June 29, 2015, SeekingAlpha.com published a report on CorMedix asserting, among other things, that: (1) CorMedix is based on a 1970s-era catheter product acquired for less than $1 million in a bankruptcy sale, apparently after at least two failed sales processes; (2) CorMedix's market size claims are greatly exaggerated; and (3) CorMedix is touting misleading clinical-data, as in-depth industry research shows its Neutrolin/Taurolidine product is a failure and “40% benefit!” versus industry standards is inaccurate. On this adverse news, shares of CorMedix fell sharply during intraday trading on June 29, 2015.
The Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by CorMedix investors. If you purchased shares of CorMedix on or before June 29, 2015, please visit the firm’s website at http://rosenlegal.com/cases-653.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
